Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500331 · ClinicalTrials.gov registry record · Phase 2
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 334
- Enrollment target
- 20
- Study locations
NCT00500331 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by GlaxoSmithKline. The registered enrollment target is 334 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00500331, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 334 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment naive patients with T2DM
Conditions Studied
Interventions
- OTHER Placebo
- DRUG pioglitazone
- DRUG GSK189075
Study Locations (20)
Florida
- GSK Investigational Site - Hollywood
- GSK Investigational Site - Miami
- GSK Investigational Site - Saint Cloud
Nevada
- GSK Investigational Site - Las Vegas
- GSK Investigational Site - Las Vegas
- GSK Investigational Site - Las Vegas
Buenos Aires
- GSK Investigational Site - Buenos Aries
- GSK Investigational Site - Ciudad Autonoma de Buenos Aires
- GSK Investigational Site - Ciudad Autónoma de Buenos Aires
Other
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Córdoba
Arizona
- GSK Investigational Site - Mesa
Louisiana
- GSK Investigational Site - Sunset
Maryland
- GSK Investigational Site - Oxon Hill
New Mexico
- GSK Investigational Site - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2007-01-23 |
| Est. Completion | 2008-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500331
The ClinicalTrials.gov registry entry for NCT00500331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (93% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00500331 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Nevada, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT00500331 about?
NCT00500331 is a clinical study titled "Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)". This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment naive patients with T2DM
What is the current status of trial NCT00500331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 334 participants. The study started on 2007-01-23. Estimated completion is 2008-02-14.
What conditions does trial NCT00500331 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00500331?
The interventions under investigation include: Placebo (OTHER), pioglitazone (DRUG), GSK189075 (DRUG).
Who is sponsoring clinical trial NCT00500331?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00500331 being conducted?
This trial has 20 study locations across Arizona, Florida, Louisiana, Maryland, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.